Posted in | News

Tianjin FAW Toyota's Plant No. 3 Begins Producing New Corolla in China

Approximately 630 people attended a line-off ceremony held today at the plant, including FAW President Zhu Yanfeng, TMC President Katsuaki Watanabe, TFTM President Shozo Takemoto and Deputy President Han Xinliang, Tianjin City officials, Japanese government officials and representatives of suppliers and dealers. To view the archived presentation of this press release please go to http://www.toyota-media.com/euen/.

At the ceremony, Watanabe said, "The TFTM Plant No. 3 reflects the steady development of the joint venture between FAW and TMC. Furthermore, the new Corolla represents a new level of product appeal, and I hope that it will be well received by Chinese customers."

According to the press release published on http://www.toyota-media.com/euen/ TFTM Plant No. 3 has an annual production capacity of 200,000 vehicles and has been equipped with numerous cutting-edge facilities, such as a paint shop that utilizes water-based paints and a welding process that adopts the Global New Body Line (GBL) system. High quality manufacturing at the plant is thus combined with environmental consideration. Approximately 3.6 billion Chinese yuan was invested in constructing the plant, which has created close to 1,700 new jobs. The new Corolla produced there will be sold by roughly 260 TFTM dealers throughout China.

TFTM began production of the VIOS compact sedan in October 2002 at Plant No. 1 and has followed this with the Corolla, Crown and REIZ, for a total of four production models. Now, with the start of production of the new Corolla--the fifth production model--at Plant No. 3, TFTM's total production capacity has increased to 420,000 vehicles a year.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.